Kaboom personal page - To The Moon

Kaboom

Kaboom

No personal profile

4Follow

21Followers

0Topic

0Badge

12-14

$Himax(HIMX)$ most of us wished we invested in Apple 20 years ago. This is not a flash in the pan company to be able to afford dividends. The financials kinda solid actually.

10-03

Sigh. This company is a joke

Stock Track | Novavax Shares Tumble 9% After Clarifying COVID Vaccine Market Guidance

06-17

$Virgin Galactic(SPCE)$ Where did my shares if I had 10 before the reverse split?

06-06

$Novavax(NVAX)$ Gut feeling it's gonna break 30 when the market opens

05-16

$SIA(C6L.SI)$ Why is the share price dropping after record earnings?

04-11

$Virgin Galactic(SPCE)$ Is this a doomed stock? Danelfin states a 9 on buy.

03-28

$C3.ai, Inc.(AI)$ Why do the stats info say it pays dividends? C3 does not pay dividends

03-11

$SINGAPORE AIRLINES LTD(C6L.SI)$ Really testing the support line.

2023-12-04

$SINGAPORE AIRLINES LTD(C6L.SI)$ If I sell my shares on 6 Dec will I still get dividends?

2023-06-14

$Kingsoft Cloud Holdings Ltd(KC)$ So the CEO buys its stocks knowing people will follow. Is he allowed to sell to cash in?

2022-10-28

$Twitter(TWTR)$So is he planning to delist?

2022-07-15

Musk has stocks in Twitter. If its share pricegoes up from this fiasco he stands to earn

Twitter Now Holds the Upper Hand in Battle Against Musk, Says Analyst

2022-06-09

Oh ffs. Every single time.

Novavax Won't Get Authorization Until the FDA Reviews Manufacturing Changes

2022-05-10

$SINGAPORE AIRLINES LTD(C6L.SI)$Time to buy

2022-02-08

Yet another major f up. When have they delivered??!!

Novavax Underdelivers on Covid Vaccine Promises

2022-01-07

$Virgin Galactic(SPCE)$I effin hate you Branson.

2022-01-05

$Aethlon Medical(AEMD)$Is this stock dead?

2021-09-08

$TAL Education Group(TAL)$Why is anyonestill buying this? I’m confused.

2021-09-07

$Entera Bio Ltd.(ENTX)$Is this stock dead?No activity at all

2021-08-23

$BioNTech SE(BNTX)$Hi anyone. I’m struggling to understand why it’s share price popped after WHO advises to halt booster shotsto wealthy nations. Can anyone please share? Thanks

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3573515033218465","uuid":"3573515033218465","gmtCreate":1610421010152,"gmtModify":1613485201709,"name":"Kaboom","pinyin":"kaboom","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/5cc3a179bc8939d7ec568911cc826578","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":21,"headSize":4,"tweetSize":256,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":2,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.10.10","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"80.74%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":381198384828768,"gmtCreate":1734110150254,"gmtModify":1734110154547,"author":{"id":"3573515033218465","authorId":"3573515033218465","name":"Kaboom","avatar":"https://static.tigerbbs.com/5cc3a179bc8939d7ec568911cc826578","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573515033218465","authorIdStr":"3573515033218465"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/HIMX\">$Himax(HIMX)$</a> most of us wished we invested in Apple 20 years ago. This is not a flash in the pan company to be able to afford dividends. The financials kinda solid actually.&nbsp;","listText":"<a href=\"https://ttm.financial/S/HIMX\">$Himax(HIMX)$</a> most of us wished we invested in Apple 20 years ago. This is not a flash in the pan company to be able to afford dividends. The financials kinda solid actually.&nbsp;","text":"$Himax(HIMX)$ most of us wished we invested in Apple 20 years ago. This is not a flash in the pan company to be able to afford dividends. The financials kinda solid actually.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/381198384828768","isVote":1,"tweetType":1,"viewCount":67,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":356179150815536,"gmtCreate":1727959883556,"gmtModify":1727959887411,"author":{"id":"3573515033218465","authorId":"3573515033218465","name":"Kaboom","avatar":"https://static.tigerbbs.com/5cc3a179bc8939d7ec568911cc826578","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573515033218465","authorIdStr":"3573515033218465"},"themes":[],"htmlText":"Sigh. This company is a joke&nbsp;","listText":"Sigh. This company is a joke&nbsp;","text":"Sigh. This company is a joke","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/356179150815536","repostId":"1119542827","repostType":2,"repost":{"id":"1119542827","kind":"news","weMediaInfo":{"introduction":"Track stock‘s movements and relevant news","home_visible":1,"media_name":"Stock Track","id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"pubTimestamp":1727959029,"share":"https://ttm.financial/m/news/1119542827?lang=&edition=fundamental","pubTime":"2024-10-03 20:37","market":"hk","language":"en","title":"Stock Track | Novavax Shares Tumble 9% After Clarifying COVID Vaccine Market Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=1119542827","media":"Stock Track","summary":"Shares of Novavax Inc.  plunged over 9% in pre-market trading on Thursday after the biotechnology company clarified that it has not reaffirmed or updated its full-year 2024 financial guidance for the U.S. COVID-19 vaccine market, contrary to a recent analyst report.On Wednesday, Novavax's stock soared nearly 19% after Jefferies analyst Roger Song suggested in a research note that the company would likely meet its 2024 revenue guidance. Song's assessment was based on a meeting with Novavax manage","content":"<p>Shares of Novavax Inc. (NVAX) plunged over 9% in pre-market trading on Thursday after the biotechnology company clarified that it has not reaffirmed or updated its full-year 2024 financial guidance for the U.S. COVID-19 vaccine market, contrary to a recent analyst report.</p>\n\n<p>On Wednesday, Novavax's stock soared nearly 19% after Jefferies analyst Roger Song suggested in a research note that the company would likely meet its 2024 revenue guidance. Song's assessment was based on a meeting with Novavax management, where he concluded that trends in this year's COVID-19 vaccine sales would follow a similar pattern as 2023.</p>\n\n<p>However, Novavax swiftly clarified that while it is aware of the analyst report, it has not provided any updates or reaffirmations regarding its full-year 2024 outlook since the Q2 2024 financial results in August. This clarification appeared to trigger a sharp reversal in investor sentiment, resulting in a significant pre-market decline in the company's share price.</p>","source":"ai_movement_en","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Novavax Shares Tumble 9% After Clarifying COVID Vaccine Market Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Novavax Shares Tumble 9% After Clarifying COVID Vaccine Market Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-10-03 20:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Novavax Inc. (NVAX) plunged over 9% in pre-market trading on Thursday after the biotechnology company clarified that it has not reaffirmed or updated its full-year 2024 financial guidance for the U.S. COVID-19 vaccine market, contrary to a recent analyst report.</p>\n\n<p>On Wednesday, Novavax's stock soared nearly 19% after Jefferies analyst Roger Song suggested in a research note that the company would likely meet its 2024 revenue guidance. Song's assessment was based on a meeting with Novavax management, where he concluded that trends in this year's COVID-19 vaccine sales would follow a similar pattern as 2023.</p>\n\n<p>However, Novavax swiftly clarified that while it is aware of the analyst report, it has not provided any updates or reaffirmations regarding its full-year 2024 outlook since the Q2 2024 financial results in August. This clarification appeared to trigger a sharp reversal in investor sentiment, resulting in a significant pre-market decline in the company's share price.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1119542827","content_text":"Shares of Novavax Inc. (NVAX) plunged over 9% in pre-market trading on Thursday after the biotechnology company clarified that it has not reaffirmed or updated its full-year 2024 financial guidance for the U.S. COVID-19 vaccine market, contrary to a recent analyst report.\nOn Wednesday, Novavax's stock soared nearly 19% after Jefferies analyst Roger Song suggested in a research note that the company would likely meet its 2024 revenue guidance. Song's assessment was based on a meeting with Novavax management, where he concluded that trends in this year's COVID-19 vaccine sales would follow a similar pattern as 2023.\nHowever, Novavax swiftly clarified that while it is aware of the analyst report, it has not provided any updates or reaffirmations regarding its full-year 2024 outlook since the Q2 2024 financial results in August. This clarification appeared to trigger a sharp reversal in investor sentiment, resulting in a significant pre-market decline in the company's share price.","news_type":1},"isVote":1,"tweetType":1,"viewCount":150,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":317846532304968,"gmtCreate":1718637737550,"gmtModify":1718637742355,"author":{"id":"3573515033218465","authorId":"3573515033218465","name":"Kaboom","avatar":"https://static.tigerbbs.com/5cc3a179bc8939d7ec568911cc826578","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573515033218465","authorIdStr":"3573515033218465"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/SPCE\">$Virgin Galactic(SPCE)$</a> Where did my shares if I had 10 before the reverse split?&nbsp;","listText":"<a href=\"https://ttm.financial/S/SPCE\">$Virgin Galactic(SPCE)$</a> Where did my shares if I had 10 before the reverse split?&nbsp;","text":"$Virgin Galactic(SPCE)$ Where did my shares if I had 10 before the reverse split?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/317846532304968","isVote":1,"tweetType":1,"viewCount":781,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":313989542731848,"gmtCreate":1717678025903,"gmtModify":1717678029529,"author":{"id":"3573515033218465","authorId":"3573515033218465","name":"Kaboom","avatar":"https://static.tigerbbs.com/5cc3a179bc8939d7ec568911cc826578","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573515033218465","authorIdStr":"3573515033218465"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/NVAX\">$Novavax(NVAX)$</a> Gut feeling it's gonna break 30 when the market opens&nbsp;","listText":"<a href=\"https://ttm.financial/S/NVAX\">$Novavax(NVAX)$</a> Gut feeling it's gonna break 30 when the market opens&nbsp;","text":"$Novavax(NVAX)$ Gut feeling it's gonna break 30 when the market opens","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/313989542731848","isVote":1,"tweetType":1,"viewCount":785,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4131781546868382","authorId":"4131781546868382","name":"代码污染","avatar":"https://community-static.tradeup.com/news/fcf147b93efd1d797afd8d0b79d8ae8c","crmLevel":8,"crmLevelSwitch":1,"idStr":"4131781546868382","authorIdStr":"4131781546868382"},"content":"You can make leeks","text":"You can make leeks","html":"You can make leeks"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":306359106470104,"gmtCreate":1715829866847,"gmtModify":1715829870678,"author":{"id":"3573515033218465","authorId":"3573515033218465","name":"Kaboom","avatar":"https://static.tigerbbs.com/5cc3a179bc8939d7ec568911cc826578","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573515033218465","authorIdStr":"3573515033218465"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/C6L.SI\">$SIA(C6L.SI)$&nbsp;</a> Why is the share price dropping after record earnings?","listText":"<a href=\"https://ttm.financial/S/C6L.SI\">$SIA(C6L.SI)$&nbsp;</a> Why is the share price dropping after record earnings?","text":"$SIA(C6L.SI)$ Why is the share price dropping after record earnings?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":29,"commentSize":6,"repostSize":142,"link":"https://ttm.financial/post/306359106470104","isVote":1,"tweetType":1,"viewCount":6233,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4091800619385590","authorId":"4091800619385590","name":"EricEr","avatar":"https://community-static.tradeup.com/news/33ffe618274ffef1122158ae15e4c3d7","crmLevel":4,"crmLevelSwitch":0,"idStr":"4091800619385590","authorIdStr":"4091800619385590"},"content":"The same is true for US stocks [happy] [happy]","text":"The same is true for US stocks [happy] [happy]","html":"The same is true for US stocks [happy] [happy]"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":293953359855728,"gmtCreate":1712797414767,"gmtModify":1712797418787,"author":{"id":"3573515033218465","authorId":"3573515033218465","name":"Kaboom","avatar":"https://static.tigerbbs.com/5cc3a179bc8939d7ec568911cc826578","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573515033218465","authorIdStr":"3573515033218465"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/SPCE\">$Virgin Galactic(SPCE)$</a> Is this a doomed stock? Danelfin states a 9 on buy.&nbsp;","listText":"<a href=\"https://ttm.financial/S/SPCE\">$Virgin Galactic(SPCE)$</a> Is this a doomed stock? Danelfin states a 9 on buy.&nbsp;","text":"$Virgin Galactic(SPCE)$ Is this a doomed stock? Danelfin states a 9 on buy.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/293953359855728","isVote":1,"tweetType":1,"viewCount":669,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":289164291358936,"gmtCreate":1711631302321,"gmtModify":1711631306335,"author":{"id":"3573515033218465","authorId":"3573515033218465","name":"Kaboom","avatar":"https://static.tigerbbs.com/5cc3a179bc8939d7ec568911cc826578","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573515033218465","authorIdStr":"3573515033218465"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/AI\">$C3.ai, Inc.(AI)$&nbsp;</a> Why do the stats info say it pays dividends? C3 does not pay dividends&nbsp;","listText":"<a href=\"https://ttm.financial/S/AI\">$C3.ai, Inc.(AI)$&nbsp;</a> Why do the stats info say it pays dividends? C3 does not pay dividends&nbsp;","text":"$C3.ai, Inc.(AI)$ Why do the stats info say it pays dividends? C3 does not pay dividends","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/289164291358936","isVote":1,"tweetType":1,"viewCount":290,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":283082352005184,"gmtCreate":1710137844346,"gmtModify":1710137849392,"author":{"id":"3573515033218465","authorId":"3573515033218465","name":"Kaboom","avatar":"https://static.tigerbbs.com/5cc3a179bc8939d7ec568911cc826578","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573515033218465","authorIdStr":"3573515033218465"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/C6L.SI\">$SINGAPORE AIRLINES LTD(C6L.SI)$&nbsp;</a> Really testing the support line.&nbsp;","listText":"<a href=\"https://ttm.financial/S/C6L.SI\">$SINGAPORE AIRLINES LTD(C6L.SI)$&nbsp;</a> Really testing the support line.&nbsp;","text":"$SINGAPORE AIRLINES LTD(C6L.SI)$ Really testing the support line.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":6,"repostSize":0,"link":"https://ttm.financial/post/283082352005184","isVote":1,"tweetType":1,"viewCount":2076,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3575763438022939","authorId":"3575763438022939","name":"SamLoo","avatar":"https://community-static.tradeup.com/news/77ca4d4ed611dbf507d41a60a2364817","crmLevel":8,"crmLevelSwitch":0,"idStr":"3575763438022939","authorIdStr":"3575763438022939"},"content":"The downside is only perhaps to $6, but the upside has been shown to go to more than $7 and beyond. Therefore worth holding if you're a long-term investor. If you're only interested in short-term gains/trading, your guess as good as mine 😇","text":"The downside is only perhaps to $6, but the upside has been shown to go to more than $7 and beyond. Therefore worth holding if you're a long-term investor. If you're only interested in short-term gains/trading, your guess as good as mine 😇","html":"The downside is only perhaps to $6, but the upside has been shown to go to more than $7 and beyond. Therefore worth holding if you're a long-term investor. If you're only interested in short-term gains/trading, your guess as good as mine 😇"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":248422706012376,"gmtCreate":1701687999234,"gmtModify":1701688001868,"author":{"id":"3573515033218465","authorId":"3573515033218465","name":"Kaboom","avatar":"https://static.tigerbbs.com/5cc3a179bc8939d7ec568911cc826578","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573515033218465","authorIdStr":"3573515033218465"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/C6L.SI\">$SINGAPORE AIRLINES LTD(C6L.SI)$&nbsp;</a>If I sell my shares on 6 Dec will I still get dividends?&nbsp;","listText":"<a href=\"https://ttm.financial/S/C6L.SI\">$SINGAPORE AIRLINES LTD(C6L.SI)$&nbsp;</a>If I sell my shares on 6 Dec will I still get dividends?&nbsp;","text":"$SINGAPORE AIRLINES LTD(C6L.SI)$ If I sell my shares on 6 Dec will I still get dividends?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":4,"repostSize":2,"link":"https://ttm.financial/post/248422706012376","isVote":1,"tweetType":1,"viewCount":2171,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187015667359888,"gmtCreate":1686697541480,"gmtModify":1686697556740,"author":{"id":"3573515033218465","authorId":"3573515033218465","name":"Kaboom","avatar":"https://static.tigerbbs.com/5cc3a179bc8939d7ec568911cc826578","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573515033218465","authorIdStr":"3573515033218465"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/KC\">$Kingsoft Cloud Holdings Ltd(KC)$&nbsp;</a>So the CEO buys its stocks knowing people will follow. Is he allowed to sell to cash in?&nbsp;","listText":"<a href=\"https://ttm.financial/S/KC\">$Kingsoft Cloud Holdings Ltd(KC)$&nbsp;</a>So the CEO buys its stocks knowing people will follow. Is he allowed to sell to cash in?&nbsp;","text":"$Kingsoft Cloud Holdings Ltd(KC)$ So the CEO buys its stocks knowing people will follow. Is he allowed to sell to cash in?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/187015667359888","isVote":1,"tweetType":1,"viewCount":663,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9986882572,"gmtCreate":1666922749496,"gmtModify":1676537831880,"author":{"id":"3573515033218465","authorId":"3573515033218465","name":"Kaboom","avatar":"https://static.tigerbbs.com/5cc3a179bc8939d7ec568911cc826578","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573515033218465","authorIdStr":"3573515033218465"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TWTR\">$Twitter(TWTR)$</a>So is he planning to delist?","listText":"<a href=\"https://ttm.financial/S/TWTR\">$Twitter(TWTR)$</a>So is he planning to delist?","text":"$Twitter(TWTR)$So is he planning to delist?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9986882572","isVote":1,"tweetType":1,"viewCount":664,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9076488554,"gmtCreate":1657891821278,"gmtModify":1676536077826,"author":{"id":"3573515033218465","authorId":"3573515033218465","name":"Kaboom","avatar":"https://static.tigerbbs.com/5cc3a179bc8939d7ec568911cc826578","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573515033218465","authorIdStr":"3573515033218465"},"themes":[],"htmlText":"Musk has stocks in Twitter. If its share pricegoes up from this fiasco he stands to earn","listText":"Musk has stocks in Twitter. If its share pricegoes up from this fiasco he stands to earn","text":"Musk has stocks in Twitter. If its share pricegoes up from this fiasco he stands to earn","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9076488554","repostId":"2251175019","repostType":4,"repost":{"id":"2251175019","kind":"highlight","pubTimestamp":1657883772,"share":"https://ttm.financial/m/news/2251175019?lang=&edition=fundamental","pubTime":"2022-07-15 19:16","market":"us","language":"en","title":"Twitter Now Holds the Upper Hand in Battle Against Musk, Says Analyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2251175019","media":"TipRanks","summary":"Whatever your opinion of the ongoing and unfolding Twitter (TWTR) – Elon Musk saga, it’s undeniably ","content":"<div>\n<p>Whatever your opinion of the ongoing and unfolding Twitter (TWTR) – Elon Musk saga, it’s undeniably popcorn worthy entertainment. At least for neutral onlookers.For those invested in the social ...</p>\n\n<a href=\"https://finance.yahoo.com/news/twitter-now-holds-upper-hand-191035103.html\">Web Link</a>\n\n</div>\n","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Twitter Now Holds the Upper Hand in Battle Against Musk, Says Analyst</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTwitter Now Holds the Upper Hand in Battle Against Musk, Says Analyst\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-07-15 19:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/twitter-now-holds-upper-hand-191035103.html><strong>TipRanks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Whatever your opinion of the ongoing and unfolding Twitter (TWTR) – Elon Musk saga, it’s undeniably popcorn worthy entertainment. At least for neutral onlookers.For those invested in the social ...</p>\n\n<a href=\"https://finance.yahoo.com/news/twitter-now-holds-upper-hand-191035103.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TWTR":"Twitter"},"source_url":"https://finance.yahoo.com/news/twitter-now-holds-upper-hand-191035103.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2251175019","content_text":"Whatever your opinion of the ongoing and unfolding Twitter (TWTR) – Elon Musk saga, it’s undeniably popcorn worthy entertainment. At least for neutral onlookers.For those invested in the social microblogging platform - or in Musk’s Tesla for that matter – it’s a more nail-biting affair. TWTR stock has been at the mercy of the real-life drama as the pendulum has swung from one side to the other. The latest development was seen as wholly positive for Twitter.On Tuesday, the company announced that it is suing Musk for breaking his agreement to buy the company for $44 billion - signed in late April. Musk’s reasoning is that Twitter has been withholding information from him, thereby breaking its side of the deal. This specifically pertains to Musk’s claim that there are far more spam bots on the platform than Twitter cares to admit.But in Twitter’s filing, the company claimed that when going after the company, Musk acted in \"bad faith\" and said that once the market began to turn following the April bid, he soured on the deal.The company also said it had made an effort to explain their bot calculations to Musk’s team while also proposing the CFO talk through any other issues with Musk personally. Musk turned down the chance to participate and refused to go over notes from the due diligence sessions.The new revelations are a game changer, says Rosenblatt analyst Barton Crockett, who has now completely “flipped” in his view of the case.“We had formerly seen meaningful risk (based largely on Musk's assertions and also a history of mDAU restatements), that Twitter was being evasive in disclosure of its spam bot calculations,” said the analyst. “That lead us to assume that Musk had leverage to extract a meaningful concession to avoid discovery damaging to Twitter in a court process. But Twitter's disclosure of very detailed efforts to explain its spam bot calculations to Musk, and Musk's reluctance to engage, largely ends our skepticism about Twitter, and instead makes us skeptical about Musk. As a result, we now see leverage on Twitter's side in this fight.”Musk might have to pay a settlement of well over $1 billion and could even be forced to conclude the deal and buy Twitter for the agreed $54.20 per share price.As such, Crockett has now upgraded TWTR’s rating from Neutral to Buy, while the price target is bumped from $33 to $52, suggesting shares will climb 42% higher over the coming months. In contrast to Crockett’s updated take, almost all other analysts remain on the sidelines. Barring one additional Buy, the stock garners 21 Holds, naturally culminating in a Hold consensus rating. However, the shares now appear undervalued to many; going by the $44.46 average price target, they are expected to change hands for ~22% premium a year from now.","news_type":1},"isVote":1,"tweetType":1,"viewCount":307,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9058307812,"gmtCreate":1654782951036,"gmtModify":1676535510093,"author":{"id":"3573515033218465","authorId":"3573515033218465","name":"Kaboom","avatar":"https://static.tigerbbs.com/5cc3a179bc8939d7ec568911cc826578","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573515033218465","authorIdStr":"3573515033218465"},"themes":[],"htmlText":"Oh ffs. Every single time.&nbsp;","listText":"Oh ffs. Every single time.&nbsp;","text":"Oh ffs. Every single time.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9058307812","repostId":"2242337483","repostType":2,"repost":{"id":"2242337483","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1654782716,"share":"https://ttm.financial/m/news/2242337483?lang=&edition=fundamental","pubTime":"2022-06-09 21:51","market":"us","language":"en","title":"Novavax Won't Get Authorization Until the FDA Reviews Manufacturing Changes","url":"https://stock-news.laohu8.com/highlight/detail?id=2242337483","media":"Dow Jones","summary":"Novavax Shares Fall 3% in Morning Trading.Novavax Won't Get Authorization Until the FDA Reviews Manu","content":"<html><head></head><body><p>Novavax Shares Fall 3% in Morning Trading.</p><p>Novavax Won&#39;t Get Authorization Until the FDA Reviews Manufacturing Changes.</p><p><img src=\"https://static.tigerbbs.com/14d82626830ceb07996ff7093b90c673\" tg-width=\"808\" tg-height=\"668\" width=\"100%\" height=\"auto\"/>Days ago, it seemed that Novavax&#39;s Covid-19 vaccine, after months of frustrating delays, would finally make it to market in the U.S. in the near term, after the Food and Drug Administration&#39;s advisors backed its authorization at a meeting on Tuesday.</p><p>Not so fast.</p><p>Early Thursday, CNBC reported that the FDA will need to review changes to the company&#39;s manufacturing process before issuing an emergency-use authorization. Novavax (ticker: NVAX) informed the FDA of those changes on June 3, CNBC said.</p><p>That could take weeks, or more. In a note on Wednesday, J.P. Morgan analyst Eric Joseph wrote that he expects a decision on an emergency-use authorization for the vaccine would come in the middle of July. Novavax told Joseph that it expected to complete its submission of data on the manufacturing changes and receive an emergency-use authorization within &#34;weeks.&#34;</p><p>Novavax shares were down 6.2% in premarket trading Thursday, to $47. That brings the stock below the $47.54 price point at which it closed on Monday, before the FDA&#39;s outside advisors voted in favor of the proposition that the vaccine&#39;s benefits outweighed its risks.</p><p>At that meeting, the director of the FDA&#39;s Center for Biologics Evaluation and Research, Dr. Peter Marks, made clear that he sees a need for Novavax&#39;s vaccine, which unlike the Pfizer <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> and Moderna <a href=\"https://laohu8.com/S/MRNA\">$(MRNA)$</a> Covid-19 vaccines, uses a well-established, protein-based approach.</p><p>&#34;Having a protein-based alternative may be more comfortable for some, in terms of their acceptance of vaccine,&#34; Marks said at the meeting. &#34;We do have a problem with vaccine uptake that is very serious in the United States, and anything that we can do to get people more comfortable to be able to accept these potentially lifesaving medical products is something we feel we are compelled to do.&#34;</p><p>Still, Novavax&#39;s manufacturing problems have been a longstanding issue, blamed for the delay in bringing the vaccine to market. Asked at the Tuesday advisory committee hearing why Novavax had been so slow at completing its submission for an emergency-use authorization, the company&#39;s chief medical officer, Dr. Filip Dubovsky, said that developing and deploying the tests to guarantee the consistency of the vaccine was what &#34;took the longest time.&#34;</p><p>Novavax said at the committee meeting that doses destined for the U.S. would be made by the Serum Institute of India, the largest vaccine manufacturer in the world by volume. In its briefing documents and presentations, the FDA said that it wouldn&#39;t consider some tests run by Novavax of its Covid-19 vaccine, due to changes in the manufacturing process and testing that had occurred over time.</p><p>Novavax shares were down 65% so far this year as of the close of trading on Wednesday, and 75.6% over the past 12 months. In his Wednesday note, J.P. Morgan&#39;s Joseph wrote that Novavax says it can make two billion doses this year.</p><p>&#34;We see upcoming regulatory submissions / label expansion and clinical readouts (Omicron variant) as key to NVAX achieving its top-line guidance of $4-5B for 2022,&#34; Joseph wrote.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Won't Get Authorization Until the FDA Reviews Manufacturing Changes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Won't Get Authorization Until the FDA Reviews Manufacturing Changes\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2022-06-09 21:51</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Novavax Shares Fall 3% in Morning Trading.</p><p>Novavax Won&#39;t Get Authorization Until the FDA Reviews Manufacturing Changes.</p><p><img src=\"https://static.tigerbbs.com/14d82626830ceb07996ff7093b90c673\" tg-width=\"808\" tg-height=\"668\" width=\"100%\" height=\"auto\"/>Days ago, it seemed that Novavax&#39;s Covid-19 vaccine, after months of frustrating delays, would finally make it to market in the U.S. in the near term, after the Food and Drug Administration&#39;s advisors backed its authorization at a meeting on Tuesday.</p><p>Not so fast.</p><p>Early Thursday, CNBC reported that the FDA will need to review changes to the company&#39;s manufacturing process before issuing an emergency-use authorization. Novavax (ticker: NVAX) informed the FDA of those changes on June 3, CNBC said.</p><p>That could take weeks, or more. In a note on Wednesday, J.P. Morgan analyst Eric Joseph wrote that he expects a decision on an emergency-use authorization for the vaccine would come in the middle of July. Novavax told Joseph that it expected to complete its submission of data on the manufacturing changes and receive an emergency-use authorization within &#34;weeks.&#34;</p><p>Novavax shares were down 6.2% in premarket trading Thursday, to $47. That brings the stock below the $47.54 price point at which it closed on Monday, before the FDA&#39;s outside advisors voted in favor of the proposition that the vaccine&#39;s benefits outweighed its risks.</p><p>At that meeting, the director of the FDA&#39;s Center for Biologics Evaluation and Research, Dr. Peter Marks, made clear that he sees a need for Novavax&#39;s vaccine, which unlike the Pfizer <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> and Moderna <a href=\"https://laohu8.com/S/MRNA\">$(MRNA)$</a> Covid-19 vaccines, uses a well-established, protein-based approach.</p><p>&#34;Having a protein-based alternative may be more comfortable for some, in terms of their acceptance of vaccine,&#34; Marks said at the meeting. &#34;We do have a problem with vaccine uptake that is very serious in the United States, and anything that we can do to get people more comfortable to be able to accept these potentially lifesaving medical products is something we feel we are compelled to do.&#34;</p><p>Still, Novavax&#39;s manufacturing problems have been a longstanding issue, blamed for the delay in bringing the vaccine to market. Asked at the Tuesday advisory committee hearing why Novavax had been so slow at completing its submission for an emergency-use authorization, the company&#39;s chief medical officer, Dr. Filip Dubovsky, said that developing and deploying the tests to guarantee the consistency of the vaccine was what &#34;took the longest time.&#34;</p><p>Novavax said at the committee meeting that doses destined for the U.S. would be made by the Serum Institute of India, the largest vaccine manufacturer in the world by volume. In its briefing documents and presentations, the FDA said that it wouldn&#39;t consider some tests run by Novavax of its Covid-19 vaccine, due to changes in the manufacturing process and testing that had occurred over time.</p><p>Novavax shares were down 65% so far this year as of the close of trading on Wednesday, and 75.6% over the past 12 months. In his Wednesday note, J.P. Morgan&#39;s Joseph wrote that Novavax says it can make two billion doses this year.</p><p>&#34;We see upcoming regulatory submissions / label expansion and clinical readouts (Omicron variant) as key to NVAX achieving its top-line guidance of $4-5B for 2022,&#34; Joseph wrote.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK1511":"疑似财技股","NVAX":"诺瓦瓦克斯医药","BK4139":"生物科技","BK4568":"美国抗疫概念","BK1117":"系统软件"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2242337483","content_text":"Novavax Shares Fall 3% in Morning Trading.Novavax Won't Get Authorization Until the FDA Reviews Manufacturing Changes.Days ago, it seemed that Novavax's Covid-19 vaccine, after months of frustrating delays, would finally make it to market in the U.S. in the near term, after the Food and Drug Administration's advisors backed its authorization at a meeting on Tuesday.Not so fast.Early Thursday, CNBC reported that the FDA will need to review changes to the company's manufacturing process before issuing an emergency-use authorization. Novavax (ticker: NVAX) informed the FDA of those changes on June 3, CNBC said.That could take weeks, or more. In a note on Wednesday, J.P. Morgan analyst Eric Joseph wrote that he expects a decision on an emergency-use authorization for the vaccine would come in the middle of July. Novavax told Joseph that it expected to complete its submission of data on the manufacturing changes and receive an emergency-use authorization within \"weeks.\"Novavax shares were down 6.2% in premarket trading Thursday, to $47. That brings the stock below the $47.54 price point at which it closed on Monday, before the FDA's outside advisors voted in favor of the proposition that the vaccine's benefits outweighed its risks.At that meeting, the director of the FDA's Center for Biologics Evaluation and Research, Dr. Peter Marks, made clear that he sees a need for Novavax's vaccine, which unlike the Pfizer $(PFE)$ and Moderna $(MRNA)$ Covid-19 vaccines, uses a well-established, protein-based approach.\"Having a protein-based alternative may be more comfortable for some, in terms of their acceptance of vaccine,\" Marks said at the meeting. \"We do have a problem with vaccine uptake that is very serious in the United States, and anything that we can do to get people more comfortable to be able to accept these potentially lifesaving medical products is something we feel we are compelled to do.\"Still, Novavax's manufacturing problems have been a longstanding issue, blamed for the delay in bringing the vaccine to market. Asked at the Tuesday advisory committee hearing why Novavax had been so slow at completing its submission for an emergency-use authorization, the company's chief medical officer, Dr. Filip Dubovsky, said that developing and deploying the tests to guarantee the consistency of the vaccine was what \"took the longest time.\"Novavax said at the committee meeting that doses destined for the U.S. would be made by the Serum Institute of India, the largest vaccine manufacturer in the world by volume. In its briefing documents and presentations, the FDA said that it wouldn't consider some tests run by Novavax of its Covid-19 vaccine, due to changes in the manufacturing process and testing that had occurred over time.Novavax shares were down 65% so far this year as of the close of trading on Wednesday, and 75.6% over the past 12 months. In his Wednesday note, J.P. Morgan's Joseph wrote that Novavax says it can make two billion doses this year.\"We see upcoming regulatory submissions / label expansion and clinical readouts (Omicron variant) as key to NVAX achieving its top-line guidance of $4-5B for 2022,\" Joseph wrote.","news_type":1},"isVote":1,"tweetType":1,"viewCount":365,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9065166034,"gmtCreate":1652155696528,"gmtModify":1676535042525,"author":{"id":"3573515033218465","authorId":"3573515033218465","name":"Kaboom","avatar":"https://static.tigerbbs.com/5cc3a179bc8939d7ec568911cc826578","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573515033218465","authorIdStr":"3573515033218465"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/C6L.SI\">$SINGAPORE AIRLINES LTD(C6L.SI)$</a>Time to buy&nbsp;","listText":"<a href=\"https://ttm.financial/S/C6L.SI\">$SINGAPORE AIRLINES LTD(C6L.SI)$</a>Time to buy&nbsp;","text":"$SINGAPORE AIRLINES LTD(C6L.SI)$Time to buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9065166034","isVote":1,"tweetType":1,"viewCount":184,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9096102191,"gmtCreate":1644322370053,"gmtModify":1676533912193,"author":{"id":"3573515033218465","authorId":"3573515033218465","name":"Kaboom","avatar":"https://static.tigerbbs.com/5cc3a179bc8939d7ec568911cc826578","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573515033218465","authorIdStr":"3573515033218465"},"themes":[],"htmlText":"Yet another major f up. When have they delivered??!!","listText":"Yet another major f up. When have they delivered??!!","text":"Yet another major f up. When have they delivered??!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9096102191","repostId":"2209058873","repostType":2,"repost":{"id":"2209058873","kind":"news","pubTimestamp":1644319503,"share":"https://ttm.financial/m/news/2209058873?lang=&edition=fundamental","pubTime":"2022-02-08 19:25","market":"us","language":"en","title":"Novavax Underdelivers on Covid Vaccine Promises","url":"https://stock-news.laohu8.com/highlight/detail?id=2209058873","media":"Reuters","summary":"(Reuters) - Novavax Inc has delivered just a small fraction of the 2 billion COVID-19 shots it plans","content":"<html><head></head><body><p>(Reuters) - <a href=\"https://laohu8.com/S/NVAX\">Novavax Inc</a> has delivered just a small fraction of the 2 billion COVID-19 shots it plans to send around the world in 2022 and has delayed first-quarter shipments in Europe and lower income countries such as the Philippines, public officials involved in their government&#39;s vaccine rollouts told Reuters.</p><p>Novavax said it has completed delivery of only around 10 million vaccine doses so far, but is moving as quickly as possible to ship its contracted supplies for this quarter.</p><p>Some shipments have been held up by regulatory processes and are waiting in a distribution warehouse to go to healthcare providers, Novavax spokesperson Amy Speak said.</p><p>Gaithersburg, Maryland-based Novavax, which had never launched a product, had ambitions to provide a vaccine for the world, promising to deliver its shots by mid-2021.</p><p>When the tiny company missed 2021 targets, buyers turned to rivals including Pfizer Inc/<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>, Moderna Inc, and Chinese drugmakers.</p><p>Shipments to the European Union, Indonesia and the Philippines were held back by a late regulatory approval from the World Health Organization (WHO), export limitations of its production partner the Serum Institute of India, and delayed approval of individual vaccine batches by European regulators, who must vet the shots before they can be distributed, according to officials in those regions.</p><p>The delivery delays have left at least <a href=\"https://laohu8.com/S/AONE.U\">one</a> country reconsidering its Novavax order.</p><p>The company has yet to deliver vaccine on its largest contract for 1.1 billion doses to COVAX - a global vaccine distribution program for poorer countries - which would make Novavax its third largest supplier, according to business data and analytics firm GlobalData Plc.</p><p>Novavax did not provide a timeline but told Reuters it expects to deliver around 80 million doses in the current quarter to COVAX, less than 10%.</p><p>A spokesperson for the GAVI vaccine alliance that co-runs COVAX with the WHO said it expected Novavax doses to be delivered soon.</p><p>&#34;It&#39;s concerning when they have been saying they have been ready to ship millions of doses but the numbers you’re hearing are different,&#34; said Mayank Mamtani, a healthcare analyst at B. Riley Securities.</p><p>Novavax is expected to earn around $5 billion in 2022 from COVID-19 vaccine sales, according to Refinitiv data.</p><p>Its two-dose vaccine has been authorized by WHO and European Union regulators, as well as countries including India, Indonesia and the Philippines.</p><p>Trial data has shown the vaccine is more than 90% effective in preventing severe illness and death.</p><p>Low- and middle-income countries will feel the pinch the most if Novavax is missing planned shipments, said Stephen Morrison, the director of the global health policy at Washington D.C. research group Center for Strategic and International Studies. &#34;It&#39;s going to be painful for COVAX and painful for its bilateral partners.&#34;</p><p>Novavax began delivering Serum Institute-produced doses to Indonesia late last year.</p><p>Although India has said Serum Institute shipped around 10 million shots to Indonesia in November and December, an Indonesian official who declined to be named said the country has received only around 200,000 doses. The Indian government has cleared 20 million Serum shots to be shipped to Indonesia, Novavax said.</p><p>RENEGOTIATING ITS CONTRACT</p><p>A Philippines official said the country has not received any of the 30 million shots it ordered.</p><p>The Philippines is renegotiating its contract and considering reducing its order from Novavax, in part because it has 96 million vaccine doses in its national stockpile, said Vaccination Secretary Carlito Galvez, head of COVID-19 vaccine procurement for Philippines. The country has authorized nine COVID vaccines.</p><p>Novavax did not comment on the Philippines deliveries or new contract.</p><p>Novavax had said it would roll out shots in Europe by January but that has been delayed, the company spokesperson said. The initial shipments from Serum Institute were delivered to its distribution facility in the Netherlands and are awaiting final regulatory clearance for release, she said.</p><p>At least two EU countries have pushed back their planned timelines for administering Novavax shots as a result, a person familiar with the matter said.</p><p>Novavax has had difficulty getting the final regulatory nod because it has yet to provide sufficient information about batches produced in India, a person familiar with discussions between Novavax and EU officials said. Under the EU deal, initial supplies to the bloc would come from India.</p><p>Dutch health authority RIVM, which is tasked with clearing the batches, declined to comment on the reason for the timing but said the vaccine will be available from early March.</p><p>“We expect to ship as soon as the testing and release is complete and we are working to make that happen as quickly as possible,” the Novavax spokesperson said.</p><p>The UK approved Novavax’s shot on Feb. 3, but the drugmaker has not said when it will begin distributing doses there.</p><p>Novavax filed for U.S. authorization late last month, almost a year after it had originally planned to do so.</p><p>Peter Shapiro, a pharmaceutical industry analyst at GlobalData, said: “The question is whether these manufacturing and logistics issues are going to get better with time.”</p></body></html>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Underdelivers on Covid Vaccine Promises</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Underdelivers on Covid Vaccine Promises\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-08 19:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/focus-novavax-underdelivers-covid-vaccine-110000940.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) - Novavax Inc has delivered just a small fraction of the 2 billion COVID-19 shots it plans to send around the world in 2022 and has delayed first-quarter shipments in Europe and lower income...</p>\n\n<a href=\"https://finance.yahoo.com/news/focus-novavax-underdelivers-covid-vaccine-110000940.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","BK4568":"美国抗疫概念","NVAX":"诺瓦瓦克斯医药"},"source_url":"https://finance.yahoo.com/news/focus-novavax-underdelivers-covid-vaccine-110000940.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2209058873","content_text":"(Reuters) - Novavax Inc has delivered just a small fraction of the 2 billion COVID-19 shots it plans to send around the world in 2022 and has delayed first-quarter shipments in Europe and lower income countries such as the Philippines, public officials involved in their government's vaccine rollouts told Reuters.Novavax said it has completed delivery of only around 10 million vaccine doses so far, but is moving as quickly as possible to ship its contracted supplies for this quarter.Some shipments have been held up by regulatory processes and are waiting in a distribution warehouse to go to healthcare providers, Novavax spokesperson Amy Speak said.Gaithersburg, Maryland-based Novavax, which had never launched a product, had ambitions to provide a vaccine for the world, promising to deliver its shots by mid-2021.When the tiny company missed 2021 targets, buyers turned to rivals including Pfizer Inc/BioNTech SE, Moderna Inc, and Chinese drugmakers.Shipments to the European Union, Indonesia and the Philippines were held back by a late regulatory approval from the World Health Organization (WHO), export limitations of its production partner the Serum Institute of India, and delayed approval of individual vaccine batches by European regulators, who must vet the shots before they can be distributed, according to officials in those regions.The delivery delays have left at least one country reconsidering its Novavax order.The company has yet to deliver vaccine on its largest contract for 1.1 billion doses to COVAX - a global vaccine distribution program for poorer countries - which would make Novavax its third largest supplier, according to business data and analytics firm GlobalData Plc.Novavax did not provide a timeline but told Reuters it expects to deliver around 80 million doses in the current quarter to COVAX, less than 10%.A spokesperson for the GAVI vaccine alliance that co-runs COVAX with the WHO said it expected Novavax doses to be delivered soon.\"It's concerning when they have been saying they have been ready to ship millions of doses but the numbers you’re hearing are different,\" said Mayank Mamtani, a healthcare analyst at B. Riley Securities.Novavax is expected to earn around $5 billion in 2022 from COVID-19 vaccine sales, according to Refinitiv data.Its two-dose vaccine has been authorized by WHO and European Union regulators, as well as countries including India, Indonesia and the Philippines.Trial data has shown the vaccine is more than 90% effective in preventing severe illness and death.Low- and middle-income countries will feel the pinch the most if Novavax is missing planned shipments, said Stephen Morrison, the director of the global health policy at Washington D.C. research group Center for Strategic and International Studies. \"It's going to be painful for COVAX and painful for its bilateral partners.\"Novavax began delivering Serum Institute-produced doses to Indonesia late last year.Although India has said Serum Institute shipped around 10 million shots to Indonesia in November and December, an Indonesian official who declined to be named said the country has received only around 200,000 doses. The Indian government has cleared 20 million Serum shots to be shipped to Indonesia, Novavax said.RENEGOTIATING ITS CONTRACTA Philippines official said the country has not received any of the 30 million shots it ordered.The Philippines is renegotiating its contract and considering reducing its order from Novavax, in part because it has 96 million vaccine doses in its national stockpile, said Vaccination Secretary Carlito Galvez, head of COVID-19 vaccine procurement for Philippines. The country has authorized nine COVID vaccines.Novavax did not comment on the Philippines deliveries or new contract.Novavax had said it would roll out shots in Europe by January but that has been delayed, the company spokesperson said. The initial shipments from Serum Institute were delivered to its distribution facility in the Netherlands and are awaiting final regulatory clearance for release, she said.At least two EU countries have pushed back their planned timelines for administering Novavax shots as a result, a person familiar with the matter said.Novavax has had difficulty getting the final regulatory nod because it has yet to provide sufficient information about batches produced in India, a person familiar with discussions between Novavax and EU officials said. Under the EU deal, initial supplies to the bloc would come from India.Dutch health authority RIVM, which is tasked with clearing the batches, declined to comment on the reason for the timing but said the vaccine will be available from early March.“We expect to ship as soon as the testing and release is complete and we are working to make that happen as quickly as possible,” the Novavax spokesperson said.The UK approved Novavax’s shot on Feb. 3, but the drugmaker has not said when it will begin distributing doses there.Novavax filed for U.S. authorization late last month, almost a year after it had originally planned to do so.Peter Shapiro, a pharmaceutical industry analyst at GlobalData, said: “The question is whether these manufacturing and logistics issues are going to get better with time.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":338,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9006045481,"gmtCreate":1641565266131,"gmtModify":1676533629712,"author":{"id":"3573515033218465","authorId":"3573515033218465","name":"Kaboom","avatar":"https://static.tigerbbs.com/5cc3a179bc8939d7ec568911cc826578","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573515033218465","authorIdStr":"3573515033218465"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/SPCE\">$Virgin Galactic(SPCE)$</a>I effin hate you Branson.&nbsp;","listText":"<a href=\"https://ttm.financial/S/SPCE\">$Virgin Galactic(SPCE)$</a>I effin hate you Branson.&nbsp;","text":"$Virgin Galactic(SPCE)$I effin hate you Branson.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9006045481","isVote":1,"tweetType":1,"viewCount":778,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9008198621,"gmtCreate":1641381229035,"gmtModify":1676533608148,"author":{"id":"3573515033218465","authorId":"3573515033218465","name":"Kaboom","avatar":"https://static.tigerbbs.com/5cc3a179bc8939d7ec568911cc826578","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573515033218465","authorIdStr":"3573515033218465"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/AEMD\">$Aethlon Medical(AEMD)$</a>Is this stock dead?","listText":"<a href=\"https://ttm.financial/S/AEMD\">$Aethlon Medical(AEMD)$</a>Is this stock dead?","text":"$Aethlon Medical(AEMD)$Is this stock dead?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9008198621","isVote":1,"tweetType":1,"viewCount":431,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":880636087,"gmtCreate":1631053654549,"gmtModify":1676530451334,"author":{"id":"3573515033218465","authorId":"3573515033218465","name":"Kaboom","avatar":"https://static.tigerbbs.com/5cc3a179bc8939d7ec568911cc826578","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573515033218465","authorIdStr":"3573515033218465"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TAL\">$TAL Education Group(TAL)$</a>Why is anyonestill buying this? I’m confused.&nbsp;","listText":"<a href=\"https://laohu8.com/S/TAL\">$TAL Education Group(TAL)$</a>Why is anyonestill buying this? I’m confused.&nbsp;","text":"$TAL Education Group(TAL)$Why is anyonestill buying this? I’m confused.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/880636087","isVote":1,"tweetType":1,"viewCount":707,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":880323918,"gmtCreate":1631021637334,"gmtModify":1676530444452,"author":{"id":"3573515033218465","authorId":"3573515033218465","name":"Kaboom","avatar":"https://static.tigerbbs.com/5cc3a179bc8939d7ec568911cc826578","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573515033218465","authorIdStr":"3573515033218465"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ENTX\">$Entera Bio Ltd.(ENTX)$</a>Is this stock dead?No activity at all&nbsp;","listText":"<a href=\"https://laohu8.com/S/ENTX\">$Entera Bio Ltd.(ENTX)$</a>Is this stock dead?No activity at all&nbsp;","text":"$Entera Bio Ltd.(ENTX)$Is this stock dead?No activity at all","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/880323918","isVote":1,"tweetType":1,"viewCount":670,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":835244568,"gmtCreate":1629724461354,"gmtModify":1676530111776,"author":{"id":"3573515033218465","authorId":"3573515033218465","name":"Kaboom","avatar":"https://static.tigerbbs.com/5cc3a179bc8939d7ec568911cc826578","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573515033218465","authorIdStr":"3573515033218465"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>Hi anyone. I’m struggling to understand why it’s share price popped after WHO advises to halt booster shotsto wealthy nations. Can anyone please share? Thanks&nbsp;","listText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>Hi anyone. I’m struggling to understand why it’s share price popped after WHO advises to halt booster shotsto wealthy nations. Can anyone please share? Thanks&nbsp;","text":"$BioNTech SE(BNTX)$Hi anyone. I’m struggling to understand why it’s share price popped after WHO advises to halt booster shotsto wealthy nations. Can anyone please share? Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/835244568","isVote":1,"tweetType":1,"viewCount":2203,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3574548457318517","authorId":"3574548457318517","name":"Thamzj","avatar":"https://static.tigerbbs.com/2a36c565a4a1acf586fb5ac50d79305e","crmLevel":3,"crmLevelSwitch":0,"idStr":"3574548457318517","authorIdStr":"3574548457318517"},"content":"Country like usa , has plans to use biontech vaccine booster months after 2nd dose. WHO cannot stop usa from doing so. China also planning use vaccine too.","text":"Country like usa , has plans to use biontech vaccine booster months after 2nd dose. WHO cannot stop usa from doing so. China also planning use vaccine too.","html":"Country like usa , has plans to use biontech vaccine booster months after 2nd dose. WHO cannot stop usa from doing so. China also planning use vaccine too."}],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":306359106470104,"gmtCreate":1715829866847,"gmtModify":1715829870678,"author":{"id":"3573515033218465","authorId":"3573515033218465","name":"Kaboom","avatar":"https://static.tigerbbs.com/5cc3a179bc8939d7ec568911cc826578","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573515033218465","idStr":"3573515033218465"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/C6L.SI\">$SIA(C6L.SI)$&nbsp;</a> Why is the share price dropping after record earnings?","listText":"<a href=\"https://ttm.financial/S/C6L.SI\">$SIA(C6L.SI)$&nbsp;</a> Why is the share price dropping after record earnings?","text":"$SIA(C6L.SI)$ Why is the share price dropping after record earnings?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":29,"commentSize":6,"repostSize":142,"link":"https://ttm.financial/post/306359106470104","isVote":1,"tweetType":1,"viewCount":6233,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4091800619385590","authorId":"4091800619385590","name":"EricEr","avatar":"https://community-static.tradeup.com/news/33ffe618274ffef1122158ae15e4c3d7","crmLevel":4,"crmLevelSwitch":0,"authorIdStr":"4091800619385590","idStr":"4091800619385590"},"content":"The same is true for US stocks [happy] [happy]","text":"The same is true for US stocks [happy] [happy]","html":"The same is true for US stocks [happy] [happy]"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":293953359855728,"gmtCreate":1712797414767,"gmtModify":1712797418787,"author":{"id":"3573515033218465","authorId":"3573515033218465","name":"Kaboom","avatar":"https://static.tigerbbs.com/5cc3a179bc8939d7ec568911cc826578","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573515033218465","idStr":"3573515033218465"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/SPCE\">$Virgin Galactic(SPCE)$</a> Is this a doomed stock? Danelfin states a 9 on buy.&nbsp;","listText":"<a href=\"https://ttm.financial/S/SPCE\">$Virgin Galactic(SPCE)$</a> Is this a doomed stock? Danelfin states a 9 on buy.&nbsp;","text":"$Virgin Galactic(SPCE)$ Is this a doomed stock? Danelfin states a 9 on buy.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/293953359855728","isVote":1,"tweetType":1,"viewCount":669,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":317846532304968,"gmtCreate":1718637737550,"gmtModify":1718637742355,"author":{"id":"3573515033218465","authorId":"3573515033218465","name":"Kaboom","avatar":"https://static.tigerbbs.com/5cc3a179bc8939d7ec568911cc826578","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573515033218465","idStr":"3573515033218465"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/SPCE\">$Virgin Galactic(SPCE)$</a> Where did my shares if I had 10 before the reverse split?&nbsp;","listText":"<a href=\"https://ttm.financial/S/SPCE\">$Virgin Galactic(SPCE)$</a> Where did my shares if I had 10 before the reverse split?&nbsp;","text":"$Virgin Galactic(SPCE)$ Where did my shares if I had 10 before the reverse split?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/317846532304968","isVote":1,"tweetType":1,"viewCount":781,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":112179532,"gmtCreate":1622857904626,"gmtModify":1704192521808,"author":{"id":"3573515033218465","authorId":"3573515033218465","name":"Kaboom","avatar":"https://static.tigerbbs.com/5cc3a179bc8939d7ec568911cc826578","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573515033218465","idStr":"3573515033218465"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AMC\">$AMC Entertainment(AMC)$</a>Please do your own research. The AMC execs sold their shares to pump it back in to the company not of greed! The Bloomberg report is so misleading and from the teats of hedge funds.&nbsp;","listText":"<a href=\"https://laohu8.com/S/AMC\">$AMC Entertainment(AMC)$</a>Please do your own research. The AMC execs sold their shares to pump it back in to the company not of greed! The Bloomberg report is so misleading and from the teats of hedge funds.&nbsp;","text":"$AMC Entertainment(AMC)$Please do your own research. The AMC execs sold their shares to pump it back in to the company not of greed! The Bloomberg report is so misleading and from the teats of hedge funds.","images":[],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":14,"commentSize":12,"repostSize":0,"link":"https://ttm.financial/post/112179532","isVote":1,"tweetType":1,"viewCount":2781,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3574806689755573","authorId":"3574806689755573","name":"我希望你不要不识抬举","avatar":"https://static.tigerbbs.com/0da9d94944d9226e0800c8c805cfa968","crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3574806689755573","idStr":"3574806689755573"},"content":"If you look at the news that Tiger directly set the top, you will know that hedging colluded with securities dealers.","text":"If you look at the news that Tiger directly set the top, you will know that hedging colluded with securities dealers.","html":"If you look at the news that Tiger directly set the top, you will know that hedging colluded with securities dealers."}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":248422706012376,"gmtCreate":1701687999234,"gmtModify":1701688001868,"author":{"id":"3573515033218465","authorId":"3573515033218465","name":"Kaboom","avatar":"https://static.tigerbbs.com/5cc3a179bc8939d7ec568911cc826578","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573515033218465","idStr":"3573515033218465"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/C6L.SI\">$SINGAPORE AIRLINES LTD(C6L.SI)$&nbsp;</a>If I sell my shares on 6 Dec will I still get dividends?&nbsp;","listText":"<a href=\"https://ttm.financial/S/C6L.SI\">$SINGAPORE AIRLINES LTD(C6L.SI)$&nbsp;</a>If I sell my shares on 6 Dec will I still get dividends?&nbsp;","text":"$SINGAPORE AIRLINES LTD(C6L.SI)$ If I sell my shares on 6 Dec will I still get dividends?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":4,"repostSize":2,"link":"https://ttm.financial/post/248422706012376","isVote":1,"tweetType":1,"viewCount":2171,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187546990,"gmtCreate":1623760312510,"gmtModify":1703818396071,"author":{"id":"3573515033218465","authorId":"3573515033218465","name":"Kaboom","avatar":"https://static.tigerbbs.com/5cc3a179bc8939d7ec568911cc826578","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573515033218465","idStr":"3573515033218465"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>Anyone knows what’s going on? Why is it dropping despite yesterday’s great news","listText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>Anyone knows what’s going on? Why is it dropping despite yesterday’s great news","text":"$Novavax(NVAX)$Anyone knows what’s going on? Why is it dropping despite yesterday’s great news","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":5,"repostSize":1,"link":"https://ttm.financial/post/187546990","isVote":1,"tweetType":1,"viewCount":2730,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3559268737601093","authorId":"3559268737601093","name":"可爱ppp","avatar":"https://static.tigerbbs.com/ca3ed1268ef84afef0c3bdc6eee25dca","crmLevel":4,"crmLevelSwitch":0,"authorIdStr":"3559268737601093","idStr":"3559268737601093"},"content":"Vaccine stocks are notoriously infamous for this. unexpected good news will trigger rally. But if we expected good efficacy since last July and results, is matter of time before profit taking","text":"Vaccine stocks are notoriously infamous for this. unexpected good news will trigger rally. But if we expected good efficacy since last July and results, is matter of time before profit taking","html":"Vaccine stocks are notoriously infamous for this. unexpected good news will trigger rally. But if we expected good efficacy since last July and results, is matter of time before profit taking"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":142575219,"gmtCreate":1626164826531,"gmtModify":1703754630918,"author":{"id":"3573515033218465","authorId":"3573515033218465","name":"Kaboom","avatar":"https://static.tigerbbs.com/5cc3a179bc8939d7ec568911cc826578","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573515033218465","idStr":"3573515033218465"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SPCE\">$Virgin Galactic(SPCE)$</a>Ok I really have no clue what’s going on. Is it due to the extra $500 million shares?","listText":"<a href=\"https://laohu8.com/S/SPCE\">$Virgin Galactic(SPCE)$</a>Ok I really have no clue what’s going on. Is it due to the extra $500 million shares?","text":"$Virgin Galactic(SPCE)$Ok I really have no clue what’s going on. Is it due to the extra $500 million shares?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":7,"repostSize":0,"link":"https://ttm.financial/post/142575219","isVote":1,"tweetType":1,"viewCount":2670,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3567575098485843","authorId":"3567575098485843","name":"股市轟炸机队长","avatar":"https://static.tigerbbs.com/1ec92b2a3335762e71e118cc8d1b3753","crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3567575098485843","idStr":"3567575098485843"},"content":"Anyway, he is not a leek. After watching the performance, of course, he has to pay and take his life to fly into space. [Cool]","text":"Anyway, he is not a leek. After watching the performance, of course, he has to pay and take his life to fly into space. [Cool]","html":"Anyway, he is not a leek. After watching the performance, of course, he has to pay and take his life to fly into space. [Cool]"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":122448017,"gmtCreate":1624631362639,"gmtModify":1703842290691,"author":{"id":"3573515033218465","authorId":"3573515033218465","name":"Kaboom","avatar":"https://static.tigerbbs.com/5cc3a179bc8939d7ec568911cc826578","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573515033218465","idStr":"3573515033218465"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>Yo if Singapore is buying it it means it’s solid. Don’t be in a hurry to dump. Their science of using moth cells&nbsp;has a lot of great implications in future vaccines and might have less complications.&nbsp;","listText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>Yo if Singapore is buying it it means it’s solid. Don’t be in a hurry to dump. Their science of using moth cells&nbsp;has a lot of great implications in future vaccines and might have less complications.&nbsp;","text":"$Novavax(NVAX)$Yo if Singapore is buying it it means it’s solid. Don’t be in a hurry to dump. Their science of using moth cells has a lot of great implications in future vaccines and might have less complications.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":4,"repostSize":1,"link":"https://ttm.financial/post/122448017","isVote":1,"tweetType":1,"viewCount":692,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3575026406777650","authorId":"3575026406777650","name":"MJ1015","avatar":"https://static.tigerbbs.com/7d80f16d168a855239ddb466b4349c1a","crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3575026406777650","idStr":"3575026406777650"},"content":"Just curious, previously i heard that Novavax Only needs one dose but why now the news said also need 2 dose? And India is prioritizing their own vaccine’s production, is it?","text":"Just curious, previously i heard that Novavax Only needs one dose but why now the news said also need 2 dose? And India is prioritizing their own vaccine’s production, is it?","html":"Just curious, previously i heard that Novavax Only needs one dose but why now the news said also need 2 dose? And India is prioritizing their own vaccine’s production, is it?"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":283082352005184,"gmtCreate":1710137844346,"gmtModify":1710137849392,"author":{"id":"3573515033218465","authorId":"3573515033218465","name":"Kaboom","avatar":"https://static.tigerbbs.com/5cc3a179bc8939d7ec568911cc826578","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573515033218465","idStr":"3573515033218465"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/C6L.SI\">$SINGAPORE AIRLINES LTD(C6L.SI)$&nbsp;</a> Really testing the support line.&nbsp;","listText":"<a href=\"https://ttm.financial/S/C6L.SI\">$SINGAPORE AIRLINES LTD(C6L.SI)$&nbsp;</a> Really testing the support line.&nbsp;","text":"$SINGAPORE AIRLINES LTD(C6L.SI)$ Really testing the support line.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":6,"repostSize":0,"link":"https://ttm.financial/post/283082352005184","isVote":1,"tweetType":1,"viewCount":2076,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3575763438022939","authorId":"3575763438022939","name":"SamLoo","avatar":"https://community-static.tradeup.com/news/77ca4d4ed611dbf507d41a60a2364817","crmLevel":8,"crmLevelSwitch":0,"authorIdStr":"3575763438022939","idStr":"3575763438022939"},"content":"The downside is only perhaps to $6, but the upside has been shown to go to more than $7 and beyond. Therefore worth holding if you're a long-term investor. If you're only interested in short-term gains/trading, your guess as good as mine 😇","text":"The downside is only perhaps to $6, but the upside has been shown to go to more than $7 and beyond. Therefore worth holding if you're a long-term investor. If you're only interested in short-term gains/trading, your guess as good as mine 😇","html":"The downside is only perhaps to $6, but the upside has been shown to go to more than $7 and beyond. Therefore worth holding if you're a long-term investor. If you're only interested in short-term gains/trading, your guess as good as mine 😇"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":147207891,"gmtCreate":1626358231013,"gmtModify":1703758629423,"author":{"id":"3573515033218465","authorId":"3573515033218465","name":"Kaboom","avatar":"https://static.tigerbbs.com/5cc3a179bc8939d7ec568911cc826578","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573515033218465","idStr":"3573515033218465"},"themes":[],"htmlText":"Don’t quite get how Nvidia can crash as the split will only make it more affordable&nbsp;","listText":"Don’t quite get how Nvidia can crash as the split will only make it more affordable&nbsp;","text":"Don’t quite get how Nvidia can crash as the split will only make it more affordable","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/147207891","repostId":"2151269095","repostType":4,"repost":{"id":"2151269095","kind":"highlight","pubTimestamp":1626354840,"share":"https://ttm.financial/m/news/2151269095?lang=&edition=fundamental","pubTime":"2021-07-15 21:14","market":"us","language":"en","title":"NVIDIA Stock Could Crash. Here's What You Should Do if It Does","url":"https://stock-news.laohu8.com/highlight/detail?id=2151269095","media":"Motley Fool","summary":"As graphics card prices start sliding, NVIDIA investors may have to relive a torrid time in the company's history.","content":"<p><b>NVIDIA</b> (NASDAQ:NVDA) has sizzled on the stock market since the beginning of 2019. Shares of the graphics specialist have jumped about 500% in just over two and a half years thanks to terrific growth in the video gaming and data center businesses.</p>\n<p>However, ominous signs are emerging in NVIDIA's biggest business, video gaming, that could give investors déjà vu, harkening back to a regrettable period in the company's history.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/427519bfaf54d082e9192ec7a7e8a671\" tg-width=\"720\" tg-height=\"387\" referrerpolicy=\"no-referrer\"><span>NVDA data by YCharts</span></p>\n<h2><b>Graphics card prices are coming down as miners start dumping GPUs</b></h2>\n<p>Graphics processing unit (GPU) prices have started pulling back from their astronomical highs of late due to several factors. However, lower demand from cryptocurrency miners seems to be the biggest growth driver behind the correction. That's not surprising, as miners reportedly bought a fourth of the total graphics cards sold in the first quarter of 2021 to mine cryptocurrencies, according&nbsp;to Jon Peddie Research.</p>\n<p>But a drop in the price of <b>Ethereum</b> (CRYPTO:ETH) and China's crackdown on <b>Bitcoin</b> (CRYPTO:BTC) have hamstrung the demand for graphics cards used for mining operations. Etherscan, an Ethereum analytics platform, recently pointed&nbsp;out that the GPU power used for mining the cryptocurrency has dropped 19% in the past month. As a result, cryptocurrency miners in China are offloading their powerful graphics cards into the second-hand market, according to a report by <i>PC Gamer</i>.</p>\n<p>NVIDIA's RTX 3070 GPU is reportedly being sold&nbsp;for just over $400 in China. That's lower than the card's $499 sticker&nbsp;price. It is also worth noting that the RTX 3070 was being sold for $1,300 in the first half of June, according to <b><a href=\"https://laohu8.com/S/EBAY\">eBay</a></b> price data collected by Tom's Hardware. As of the end of the first week of July, the card's price had come down to just over $1,080.</p>\n<p>GPU prices in Germany have also dropped at a breakneck pace. The price premium of NVIDIA's RTX 30 series cards has come down to 153% of the manufacturer's suggested retail price (MSRP) in the first week of July, compared to a whopping 304% in the middle of May, according&nbsp;to a third-party report.</p>\n<h2><b>NVIDIA has been hit hard in the past</b></h2>\n<p>NVIDIA was hurt big time by a GPU price crash back in 2018 once cryptocurrency miners decided to offload their graphics cards in the preowned market. The excess graphics card inventory in the wake of the cryptocurrency mining bust burnt investors as NVIDIA's fortunes declined.</p>\n<p>The recent price correction indicates history may repeat itself and wreck NVIDIA's momentum. After all, the chipmaker's revenue in the fourth quarter of fiscal 2019 for the three months ending Jan. 27, 2019, sunk 24% year over year in the aftermath of the cryptocurrency mining bust. It took the company a year to recover from that shock. NVIDIA's revenue in fiscal 2020 dipped&nbsp;7% before it regained its mojo thanks to strong demand from the video gaming and the data center segments.</p>\n<p>However, long-term investors have no reason to worry, despite these developments that have caused NVIDIA pain in the past. That's because the demand for its latest cards is so strong that NVIDIA has reportedly decided to cut production of the old-generation RTX 2060 graphics card in half to increase the supply of the RTX 30 series cards. Additionally, reports indicate that NVIDIA is already working to increase the production of the aggressively priced RTX 3060 card to meet strong demand.</p>\n<p>So, even if gaming enthusiasts decide to buy a preowned graphics card from miners -- which isn't always a good idea&nbsp;as they may have been subjected to long hours of operation and could be prone to wearing out faster -- NVIDIA will still have enough end-market demand to fill.</p>\n<p>Consider this: Only 15% of NVIDIA's installed graphics card user base of 140 million is running the RTX series cards. A short-term disturbance in the GPU market's demand-supply dynamics is unlikely to change the long-term picture. Jon Peddie Research estimates that discrete GPU sales could generate&nbsp;$54 billion in revenue by 2025, a sharp jump from last year's revenue of $23.6 billion thanks to the growth in video gaming. NVIDIA controls&nbsp;80% of this market.</p>\n<p>Savvy investors would do well to consider buying more NVIDIA stock if the cryptocurrency bust sends its shares packing. After all, analysts expect NVIDIA's earnings to grow at more than 26% a year for the next five years, suggesting this is a top growth stock that's worth buying on its rare dips.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NVIDIA Stock Could Crash. Here's What You Should Do if It Does</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNVIDIA Stock Could Crash. Here's What You Should Do if It Does\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-15 21:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/15/nvidia-stock-could-crash-heres-what-you-should-do/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NVIDIA (NASDAQ:NVDA) has sizzled on the stock market since the beginning of 2019. Shares of the graphics specialist have jumped about 500% in just over two and a half years thanks to terrific growth ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/15/nvidia-stock-could-crash-heres-what-you-should-do/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVDA":"英伟达"},"source_url":"https://www.fool.com/investing/2021/07/15/nvidia-stock-could-crash-heres-what-you-should-do/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2151269095","content_text":"NVIDIA (NASDAQ:NVDA) has sizzled on the stock market since the beginning of 2019. Shares of the graphics specialist have jumped about 500% in just over two and a half years thanks to terrific growth in the video gaming and data center businesses.\nHowever, ominous signs are emerging in NVIDIA's biggest business, video gaming, that could give investors déjà vu, harkening back to a regrettable period in the company's history.\nNVDA data by YCharts\nGraphics card prices are coming down as miners start dumping GPUs\nGraphics processing unit (GPU) prices have started pulling back from their astronomical highs of late due to several factors. However, lower demand from cryptocurrency miners seems to be the biggest growth driver behind the correction. That's not surprising, as miners reportedly bought a fourth of the total graphics cards sold in the first quarter of 2021 to mine cryptocurrencies, according to Jon Peddie Research.\nBut a drop in the price of Ethereum (CRYPTO:ETH) and China's crackdown on Bitcoin (CRYPTO:BTC) have hamstrung the demand for graphics cards used for mining operations. Etherscan, an Ethereum analytics platform, recently pointed out that the GPU power used for mining the cryptocurrency has dropped 19% in the past month. As a result, cryptocurrency miners in China are offloading their powerful graphics cards into the second-hand market, according to a report by PC Gamer.\nNVIDIA's RTX 3070 GPU is reportedly being sold for just over $400 in China. That's lower than the card's $499 sticker price. It is also worth noting that the RTX 3070 was being sold for $1,300 in the first half of June, according to eBay price data collected by Tom's Hardware. As of the end of the first week of July, the card's price had come down to just over $1,080.\nGPU prices in Germany have also dropped at a breakneck pace. The price premium of NVIDIA's RTX 30 series cards has come down to 153% of the manufacturer's suggested retail price (MSRP) in the first week of July, compared to a whopping 304% in the middle of May, according to a third-party report.\nNVIDIA has been hit hard in the past\nNVIDIA was hurt big time by a GPU price crash back in 2018 once cryptocurrency miners decided to offload their graphics cards in the preowned market. The excess graphics card inventory in the wake of the cryptocurrency mining bust burnt investors as NVIDIA's fortunes declined.\nThe recent price correction indicates history may repeat itself and wreck NVIDIA's momentum. After all, the chipmaker's revenue in the fourth quarter of fiscal 2019 for the three months ending Jan. 27, 2019, sunk 24% year over year in the aftermath of the cryptocurrency mining bust. It took the company a year to recover from that shock. NVIDIA's revenue in fiscal 2020 dipped 7% before it regained its mojo thanks to strong demand from the video gaming and the data center segments.\nHowever, long-term investors have no reason to worry, despite these developments that have caused NVIDIA pain in the past. That's because the demand for its latest cards is so strong that NVIDIA has reportedly decided to cut production of the old-generation RTX 2060 graphics card in half to increase the supply of the RTX 30 series cards. Additionally, reports indicate that NVIDIA is already working to increase the production of the aggressively priced RTX 3060 card to meet strong demand.\nSo, even if gaming enthusiasts decide to buy a preowned graphics card from miners -- which isn't always a good idea as they may have been subjected to long hours of operation and could be prone to wearing out faster -- NVIDIA will still have enough end-market demand to fill.\nConsider this: Only 15% of NVIDIA's installed graphics card user base of 140 million is running the RTX series cards. A short-term disturbance in the GPU market's demand-supply dynamics is unlikely to change the long-term picture. Jon Peddie Research estimates that discrete GPU sales could generate $54 billion in revenue by 2025, a sharp jump from last year's revenue of $23.6 billion thanks to the growth in video gaming. NVIDIA controls 80% of this market.\nSavvy investors would do well to consider buying more NVIDIA stock if the cryptocurrency bust sends its shares packing. After all, analysts expect NVIDIA's earnings to grow at more than 26% a year for the next five years, suggesting this is a top growth stock that's worth buying on its rare dips.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1703,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":895744253,"gmtCreate":1628775872572,"gmtModify":1676529850867,"author":{"id":"3573515033218465","authorId":"3573515033218465","name":"Kaboom","avatar":"https://static.tigerbbs.com/5cc3a179bc8939d7ec568911cc826578","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573515033218465","idStr":"3573515033218465"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>Gosh. What’s going on again. The delay in FDA is old news!","listText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>Gosh. What’s going on again. The delay in FDA is old news!","text":"$Novavax(NVAX)$Gosh. What’s going on again. The delay in FDA is old news!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":2,"link":"https://ttm.financial/post/895744253","isVote":1,"tweetType":1,"viewCount":921,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":132282488,"gmtCreate":1622091840344,"gmtModify":1704179312379,"author":{"id":"3573515033218465","authorId":"3573515033218465","name":"Kaboom","avatar":"https://static.tigerbbs.com/5cc3a179bc8939d7ec568911cc826578","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573515033218465","idStr":"3573515033218465"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/Y92.SI\">$THAI BEVERAGE PUBLIC CO LTD(Y92.SI)$</a>0.15 THB per share??!!&nbsp;","listText":"<a href=\"https://laohu8.com/S/Y92.SI\">$THAI BEVERAGE PUBLIC CO LTD(Y92.SI)$</a>0.15 THB per share??!!&nbsp;","text":"$THAI BEVERAGE PUBLIC CO LTD(Y92.SI)$0.15 THB per share??!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":7,"repostSize":0,"link":"https://ttm.financial/post/132282488","isVote":1,"tweetType":1,"viewCount":263,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3583895447755437","authorId":"3583895447755437","name":"gingy","avatar":"https://static.tigerbbs.com/29f400e3962b56b8602b0cd0dedf74e5","crmLevel":3,"crmLevelSwitch":0,"authorIdStr":"3583895447755437","idStr":"3583895447755437"},"content":"https://www.dividends.sg/ is the site with all dividend info","text":"https://www.dividends.sg/ is the site with all dividend info","html":"https://www.dividends.sg/ is the site with all dividend info"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":102555502,"gmtCreate":1620225966206,"gmtModify":1704340488632,"author":{"id":"3573515033218465","authorId":"3573515033218465","name":"Kaboom","avatar":"https://static.tigerbbs.com/5cc3a179bc8939d7ec568911cc826578","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573515033218465","idStr":"3573515033218465"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>You suck&nbsp;","listText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>You suck&nbsp;","text":"$Tesla Motors(TSLA)$You suck","images":[{"img":"https://static.tigerbbs.com/a14f29d45637dc4e6d6e916a1d5967e6","width":"750","height":"1068"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":5,"repostSize":0,"link":"https://ttm.financial/post/102555502","isVote":1,"tweetType":1,"viewCount":375,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":377288680,"gmtCreate":1619530775040,"gmtModify":1704725494148,"author":{"id":"3573515033218465","authorId":"3573515033218465","name":"Kaboom","avatar":"https://static.tigerbbs.com/5cc3a179bc8939d7ec568911cc826578","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573515033218465","idStr":"3573515033218465"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>Still believing in it? Bought at 830. Should I cut my losses?&nbsp;","listText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>Still believing in it? Bought at 830. Should I cut my losses?&nbsp;","text":"$Tesla Motors(TSLA)$Still believing in it? Bought at 830. Should I cut my losses?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":6,"repostSize":0,"link":"https://ttm.financial/post/377288680","isVote":1,"tweetType":1,"viewCount":755,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3560632730543985","authorId":"3560632730543985","name":"小狗1122","avatar":"https://static.tigerbbs.com/d80f2ee274d56c380ab8b3789038f83b","crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"3560632730543985","idStr":"3560632730543985"},"content":"I'm 850...","text":"I'm 850...","html":"I'm 850..."}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9006045481,"gmtCreate":1641565266131,"gmtModify":1676533629712,"author":{"id":"3573515033218465","authorId":"3573515033218465","name":"Kaboom","avatar":"https://static.tigerbbs.com/5cc3a179bc8939d7ec568911cc826578","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573515033218465","idStr":"3573515033218465"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/SPCE\">$Virgin Galactic(SPCE)$</a>I effin hate you Branson.&nbsp;","listText":"<a href=\"https://ttm.financial/S/SPCE\">$Virgin Galactic(SPCE)$</a>I effin hate you Branson.&nbsp;","text":"$Virgin Galactic(SPCE)$I effin hate you Branson.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9006045481","isVote":1,"tweetType":1,"viewCount":778,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":892094686,"gmtCreate":1628609119745,"gmtModify":1676529797216,"author":{"id":"3573515033218465","authorId":"3573515033218465","name":"Kaboom","avatar":"https://static.tigerbbs.com/5cc3a179bc8939d7ec568911cc826578","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573515033218465","idStr":"3573515033218465"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>Love this stock btw","listText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>Love this stock btw","text":"$Novavax(NVAX)$Love this stock btw","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/892094686","isVote":1,"tweetType":1,"viewCount":41,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":149802190,"gmtCreate":1625712472110,"gmtModify":1703746922478,"author":{"id":"3573515033218465","authorId":"3573515033218465","name":"Kaboom","avatar":"https://static.tigerbbs.com/5cc3a179bc8939d7ec568911cc826578","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573515033218465","idStr":"3573515033218465"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>The retail investors are just so edgy. There’s still the alpha strain thatneeds vaccinations. And the news from Tiger is so slow!!&nbsp;","listText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>The retail investors are just so edgy. There’s still the alpha strain thatneeds vaccinations. And the news from Tiger is so slow!!&nbsp;","text":"$Novavax(NVAX)$The retail investors are just so edgy. There’s still the alpha strain thatneeds vaccinations. And the news from Tiger is so slow!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/149802190","isVote":1,"tweetType":1,"viewCount":487,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3583318222987864","authorId":"3583318222987864","name":"TheMilkyWay","avatar":"https://static.tigerbbs.com/190d59bcbcc876e15543cbd430d8c1f2","crmLevel":3,"crmLevelSwitch":1,"authorIdStr":"3583318222987864","idStr":"3583318222987864"},"content":"Unlikely due to the Delta news. Look at the whole market. Mainly the FAANGs supporting it, even they are are falling a little. Hold tight. I made the mistake of buying too early in the dip.","text":"Unlikely due to the Delta news. Look at the whole market. Mainly the FAANGs supporting it, even they are are falling a little. Hold tight. I made the mistake of buying too early in the dip.","html":"Unlikely due to the Delta news. Look at the whole market. Mainly the FAANGs supporting it, even they are are falling a little. Hold tight. I made the mistake of buying too early in the dip."}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":122457588,"gmtCreate":1624631195144,"gmtModify":1703842284830,"author":{"id":"3573515033218465","authorId":"3573515033218465","name":"Kaboom","avatar":"https://static.tigerbbs.com/5cc3a179bc8939d7ec568911cc826578","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573515033218465","idStr":"3573515033218465"},"themes":[],"htmlText":"Give it a few years. This is long term. It might not reach as high as TESLA but the % gains are what matters. I’m buying more of NIOevery few weeks.&nbsp;","listText":"Give it a few years. This is long term. It might not reach as high as TESLA but the % gains are what matters. I’m buying more of NIOevery few weeks.&nbsp;","text":"Give it a few years. This is long term. It might not reach as high as TESLA but the % gains are what matters. I’m buying more of NIOevery few weeks.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/122457588","repostId":"1198714523","repostType":2,"repost":{"id":"1198714523","kind":"news","pubTimestamp":1624611463,"share":"https://ttm.financial/m/news/1198714523?lang=&edition=fundamental","pubTime":"2021-06-25 16:57","market":"us","language":"en","title":"NIO Still Has Significant Upside Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=1198714523","media":"seekingalpha","summary":"Tesla’s valuation, however, is still 10x larger than NIO, which suggests there may be plenty of upside left. NIO could become in EVs what Alibaba is to Amazon in e-commerce.Still, one could argue that much if not all of those growth opportunities have been priced into the stock - which some havecalled the EV bubble. This, indeed, led me to review my position in NIO. Upon review, while there could certainly be downside, one could also argue that NIO is following a similar trajectory as Tesla .Tes","content":"<p><b>Summary</b></p>\n<ul>\n <li>NIO is already well over a 10-bagger.</li>\n <li>Tesla’s valuation, however, is still 10x larger than NIO, which suggests there may be plenty of upside left. NIO could become in EVs what Alibaba is to Amazon in e-commerce.</li>\n <li>There are many EV competitors, but NIO has a proven track record of growth and innovation with international expansion, ADAS, autonomous driving and ADaaS, and battery swapping and BaaS.</li>\n</ul>\n<p><b>Investment Thesis</b></p>\n<p>NIO(NYSE:NIO)was far from the largest holding in my portfolio, but has grown well over 10x since the midst of its funding issues in late 2019. This was driven by a strong post-COVID-19 rebound and further growth of its EV sales. Further optionality was introduced with capacity expansion, the new, innovative BaaS business model, and potential international expansion to Europe.</p>\n<p>Still, one could argue that much if not all of those growth opportunities have been priced into the stock - which some havecalled the EV bubble. This, indeed, led me to review my position in NIO. Upon review, while there could certainly be downside, one could also argue that NIO is following a similar trajectory as Tesla (TSLA).</p>\n<p>Tesla stock had a similar success in 2020, which was capped off by its introduction in the S&amp;P 500. This arguably supports the view that EVs are, in fact, not a bubble. NIO, in that regard, should be regarded as the Chinese Tesla, and hence poised for further growth. China is also poised to become the silicon valley of EVs and also has supportive regulation towards autonomous driving.</p>\n<p>Nevertheless, there are many competitors in EVs, not the least in China as well (also from Tesla). However, NIO is still one of the leading start-ups positioned to capitalize on this opportunity, with its proven track record of innovation and growth.</p>\n<p><b>Automotive disruption</b></p>\n<p>The automotive industry is undergoing major changes. The first major trend is towards energy sustainability. This has fueled the growth of EVs. Secondly, there is a strong economic incentive towards autonomous driving (called the \"passenger economy\"), which will further revolutionize transportation.</p>\n<p>This means this industry is open for disruption. This is indeed already unfolding, as can be seen in the trajectory of Tesla through the last decade, as one of the hallmarks of this.</p>\n<p>Even though it is an old, capital intensive business, Tesla proves that investors are willing to pay up to be part of this revolution. As noted, Tesla capped this off by its S&amp;P 500 inclusion and 500k deliveries in 2020, with continued strong growth at scale into 2021.</p>\n<p>In short, even though it could be seen as an old business, there is a large, greenfield opportunity in the drive towards electric, autonomous transportation. Hence, to be leading this disruption requires innovation.</p>\n<p><b>NIO: Chinese Tesla</b></p>\n<p>This opportunity is arguably so large that there does not necessarily have to be a winner-takes-all. Automotive is such a large market that it could be likened to e-commerce, for example. Amazon (AMZN) has been one of the largest beneficiaries of this secular growth trend. However, there are many others who have achieved a large scale and valuation growth, including Alibaba (BABA) and MercadoLibre (MELI).</p>\n<p>To that end, NIO is positioned to become in EVs and AVs what Alibaba is to Amazon in e-commerce: the Chinese Tesla.</p>\n<p>NIO is a relatively young start-up, founded on the same premise of being a pure play EV automotive company, while also investing to be at forefront of ADAS and autonomous driving. It had a strong partnership with Mobileye. It was the first adopter of the former's EyeQ4 chip in 2018. NIO was also announced to be the first adopter of Mobileye's self-driving system, in 2022. This would likely be several years ahead of others, as Mobileye is targeting a 2025 introduction of (a broader introduction of) consumer AVs.</p>\n<p>It is, however, not entirely sure if (and perhaps even unlikely that) this Mobileye-powered autonomous vehicle will still launch, as going forward NIO is continuing with Nvidia (NVDA) hardware and developing its own software. In any case, NIO's timeline is unchanged, although it is not sure if NIO's own software will be as capable as Mobileye's. I previously covered this aspect of NIO here:NIO Stock: Autonomous Driving Too Good To Be True.</p>\n<p>In any case, NIO will bring another first to market with its Autonomous Driving-as-a-Service model or ADaaS. This will provide customer access to its autonomous driving capabilities through a monthly subscription.</p>\n<p>While there had been some funding issues and a slowdown in the midst of COVID-19, the image below shows that growth returned quickly. More recently, there have been issues due to the chip shortage, but those are obviously quite similar for the whole industry.</p>\n<p><img src=\"https://static.tigerbbs.com/1373049969409b7fa8a90c380b6204e0\" tg-width=\"570\" tg-height=\"368\" referrerpolicy=\"no-referrer\"></p>\n<p>NIO's track record of growth and innovation is further completed by its introduction of the BaaS business model and plans for international expansion to Europe in 2021.</p>\n<p>BaaS or Battery-as-a-Service means that the EV is bought without the battery, which reduces the upfront price. The battery is then acquired separately through a subscription. BaaS was introduced in the second half of 2020 and quickly achieved a significant uptake of ~40%. BaaS also further complements NIO's previous innovation of battery swapping.</p>\n<p>Hence, this shows NIO is a leading innovator in the Chinese EV market, while investing to also lead the second, autonomous inflection. This is also a major market, as China is targeting a 25% EV market share by 2025. It could quickly become the silicon valley of EVs and even AVs. NIO's international ambition further underlines its leading position.</p>\n<p><b>Valuation</b></p>\n<p>Some have called EVs a bubble. Both Tesla and NIO stock were on the order of a 10-bagger in 2020. In the comments below many articles, Tesla's valuation and deliveries are compared to the traditional OEMs. Supposedly this should show the large discrepancy in valuation.</p>\n<p>Nevertheless, arguably this is not a bubble as the transition to EVs and subsequently AVs marks a major inflection. This means it is a large, largely greenfield growth opportunity. Hence, investors are willing to pay for this growth by investing in the companies who are leading. Moreover, EVs and AVs are also much closer aligned to tech investing, where higher valuations are more common.</p>\n<p>This is, of course, in spite of automotive being notorious for its capital intensity. NIO for its part (partly) solves this by not producing its vehicles itself, but partnering for manufacturing.</p>\n<p>There are other examples in tech where those who are seen as growth companies are rewarded with incredible valuations. For example, Nvidia has achieved almost 2x the valuation of Intel (INTC), despite over 3x lower revenue. TSMC (TSM) has over 2x the valuation of Intel despite almost 2x lower revenue. Of course, Nvidia and TSMC are growing faster than Intel, but that proves the point that high growth is often rewarded with perhaps unrealistic valuations.</p>\n<p>With regards to NIO's valuation, it (still) has ~10x lower market cap than Tesla (to be precise, about 8x at the time of writing), but also ~10x lower deliveries. Hence, NIO's valuation is in line with its bigger peer.</p>\n<p>Nevertheless, as a smaller company, it is arguably NIO who that the largest relative growth prospects ahead. For example, Tesla investors who want to see substantial shareholder returns going forward have to bank on Tesla's goal to achieve 20M deliveries by 2030, which would be over a fifth of the total global vehicle market.</p>\n<p>If NIO for its part would be able to translate its innovation into continued, sustained growth, similar to Tesla, then there should be no reason for NIO to not continue to track the valuation of Tesla. This means NIO, indeed, may have another 10x upside or so if it closes the gap to Tesla in scale.</p>\n<p>From that view, NIO is lagging behind Tesla by multiple years, in both deliveries and market cap. The last comment could be as analogous to for examplePinterest(PINS), which is a company Iarguedwas lagging by several years to Facebook (FB).</p>\n<p><b>Risks</b></p>\n<p>Of course, there are major risks. Mainly, this thesis is based on two assumptions:</p>\n<ul>\n <li>Tesla and other EV/AV stocks will continue to grow and receive elevated valuations as these trends continue to unfold;</li>\n <li>NIO is best positioned to most closely track Tesla's business and stock performance.</li>\n</ul>\n<p>Any decrease in (relative) valuation could result in downside. For example, Tesla's ambition as laid out at its fall 2020 Battery Day event called for Tesla to achieve a scale of 20 million units by 2030. Hence, it is likely at least some part of that ambition for further growth is already priced into the stock.</p>\n<p>Needless to say, not every automotive or EV company will be able to achieve a scale of 20M units, as the global automotive market is below 100M units. There is both competition from traditional OEMs such as GM (GM) and Volkswagen, as well as other Chinese companiessuch as XPeng(XPEV).</p>\n<p>Additionally, although China seems to be one the largest markets for EVs in the near future, Tesla itself has already built its own Gigafactory in China, further increasing competition. Although the reverse is also partly true given NIO's own international expansion.</p>\n<p>The last risk for NIO growth it that is has expressed that it wants to remain a premium brand with relatively high ASPs (average selling prices). While this implies NIO could have above-average gross margins, it may nevertheless lower NIO's addressable market and hence potential future growth.</p>\n<p>Further, while NIO is heavily investing in autonomous driving and seems to be at the forefront of this next major inflection, it is ultimately reliant on third-party silicon vendors like Nvidia. This insight means pretty much by definition that AV technology may not remain a differentiated capability, as others will be able to buy the same off-the-shelf systems. Although as noted NIO is developing its own software, that itselfis also a riskgiven the difficulty in creating a scalable and reliable AV system.</p>\n<p>As described, though, NIO is a clear, leading innovator, and has achieved a strong brand value. This arguably makes it the strongest candidate to become the closest to a 'Chinese Tesla'.</p>\n<p><b>Takeaway</b></p>\n<p>In the last 18 months or so, there has been a major shift in investment sentiment around EV companies. Tesla has seen 10-bagger returns. So when evaluating NIO, after its own 10-bagger returns (or more), to a valuation closer to $100B than $10B, on the surface this may change the investment narrative.</p>\n<p>However, at least a portion of NIO's large shareholder returns was because of its financial issues, which it has overcome; NIO's valuation is not significantly different from Tesla, for one. Meanwhile, its still much lower scale arguably leaves much room for upside.</p>\n<p>NIO's stock is based on NIO's growth to capitalize on the two-fold disruption of EVs and AVs in the automotive industry. NIO already has a proven track record of growth and innovation with battery swap, ADAS, autonomous driving (although with some increased risks given its change of supplier), ADaaS, BaaS, and even international expansion.</p>\n<p>While far from every company will be able to achieve a similar scale as Tesla, NIO clearly remains positioned to be successful in this space, which represents a large, greenfield opportunity in both the Chinese and international push towards electric and autonomous driving.</p>\n<p>This means NIO's valuation is both the risk and the reward. The reward is that NIO could realistically still expand by another 10x if it continues to trade at a similar valuation as Tesla, while closing the gap in scale. I likened NIO to the Alibaba of EVs: the Chinese counterpart of Amazon in EVs. The risk is NIO's ability to execute and deliver on its growth opportunity, as well as (just as importantly) as Tesla's and other EV stocks' valuation not collapsing on changes in investor sentiment.</p>\n<p>The bottom line (since NIO's peak in February) is that the potential opportunity that still lies ahead slightly outweighs the risk.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NIO Still Has Significant Upside Potential</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNIO Still Has Significant Upside Potential\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-25 16:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4436519-nio-still-has-upside-potential><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nNIO is already well over a 10-bagger.\nTesla’s valuation, however, is still 10x larger than NIO, which suggests there may be plenty of upside left. NIO could become in EVs what Alibaba is to ...</p>\n\n<a href=\"https://seekingalpha.com/article/4436519-nio-still-has-upside-potential\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来"},"source_url":"https://seekingalpha.com/article/4436519-nio-still-has-upside-potential","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1198714523","content_text":"Summary\n\nNIO is already well over a 10-bagger.\nTesla’s valuation, however, is still 10x larger than NIO, which suggests there may be plenty of upside left. NIO could become in EVs what Alibaba is to Amazon in e-commerce.\nThere are many EV competitors, but NIO has a proven track record of growth and innovation with international expansion, ADAS, autonomous driving and ADaaS, and battery swapping and BaaS.\n\nInvestment Thesis\nNIO(NYSE:NIO)was far from the largest holding in my portfolio, but has grown well over 10x since the midst of its funding issues in late 2019. This was driven by a strong post-COVID-19 rebound and further growth of its EV sales. Further optionality was introduced with capacity expansion, the new, innovative BaaS business model, and potential international expansion to Europe.\nStill, one could argue that much if not all of those growth opportunities have been priced into the stock - which some havecalled the EV bubble. This, indeed, led me to review my position in NIO. Upon review, while there could certainly be downside, one could also argue that NIO is following a similar trajectory as Tesla (TSLA).\nTesla stock had a similar success in 2020, which was capped off by its introduction in the S&P 500. This arguably supports the view that EVs are, in fact, not a bubble. NIO, in that regard, should be regarded as the Chinese Tesla, and hence poised for further growth. China is also poised to become the silicon valley of EVs and also has supportive regulation towards autonomous driving.\nNevertheless, there are many competitors in EVs, not the least in China as well (also from Tesla). However, NIO is still one of the leading start-ups positioned to capitalize on this opportunity, with its proven track record of innovation and growth.\nAutomotive disruption\nThe automotive industry is undergoing major changes. The first major trend is towards energy sustainability. This has fueled the growth of EVs. Secondly, there is a strong economic incentive towards autonomous driving (called the \"passenger economy\"), which will further revolutionize transportation.\nThis means this industry is open for disruption. This is indeed already unfolding, as can be seen in the trajectory of Tesla through the last decade, as one of the hallmarks of this.\nEven though it is an old, capital intensive business, Tesla proves that investors are willing to pay up to be part of this revolution. As noted, Tesla capped this off by its S&P 500 inclusion and 500k deliveries in 2020, with continued strong growth at scale into 2021.\nIn short, even though it could be seen as an old business, there is a large, greenfield opportunity in the drive towards electric, autonomous transportation. Hence, to be leading this disruption requires innovation.\nNIO: Chinese Tesla\nThis opportunity is arguably so large that there does not necessarily have to be a winner-takes-all. Automotive is such a large market that it could be likened to e-commerce, for example. Amazon (AMZN) has been one of the largest beneficiaries of this secular growth trend. However, there are many others who have achieved a large scale and valuation growth, including Alibaba (BABA) and MercadoLibre (MELI).\nTo that end, NIO is positioned to become in EVs and AVs what Alibaba is to Amazon in e-commerce: the Chinese Tesla.\nNIO is a relatively young start-up, founded on the same premise of being a pure play EV automotive company, while also investing to be at forefront of ADAS and autonomous driving. It had a strong partnership with Mobileye. It was the first adopter of the former's EyeQ4 chip in 2018. NIO was also announced to be the first adopter of Mobileye's self-driving system, in 2022. This would likely be several years ahead of others, as Mobileye is targeting a 2025 introduction of (a broader introduction of) consumer AVs.\nIt is, however, not entirely sure if (and perhaps even unlikely that) this Mobileye-powered autonomous vehicle will still launch, as going forward NIO is continuing with Nvidia (NVDA) hardware and developing its own software. In any case, NIO's timeline is unchanged, although it is not sure if NIO's own software will be as capable as Mobileye's. I previously covered this aspect of NIO here:NIO Stock: Autonomous Driving Too Good To Be True.\nIn any case, NIO will bring another first to market with its Autonomous Driving-as-a-Service model or ADaaS. This will provide customer access to its autonomous driving capabilities through a monthly subscription.\nWhile there had been some funding issues and a slowdown in the midst of COVID-19, the image below shows that growth returned quickly. More recently, there have been issues due to the chip shortage, but those are obviously quite similar for the whole industry.\n\nNIO's track record of growth and innovation is further completed by its introduction of the BaaS business model and plans for international expansion to Europe in 2021.\nBaaS or Battery-as-a-Service means that the EV is bought without the battery, which reduces the upfront price. The battery is then acquired separately through a subscription. BaaS was introduced in the second half of 2020 and quickly achieved a significant uptake of ~40%. BaaS also further complements NIO's previous innovation of battery swapping.\nHence, this shows NIO is a leading innovator in the Chinese EV market, while investing to also lead the second, autonomous inflection. This is also a major market, as China is targeting a 25% EV market share by 2025. It could quickly become the silicon valley of EVs and even AVs. NIO's international ambition further underlines its leading position.\nValuation\nSome have called EVs a bubble. Both Tesla and NIO stock were on the order of a 10-bagger in 2020. In the comments below many articles, Tesla's valuation and deliveries are compared to the traditional OEMs. Supposedly this should show the large discrepancy in valuation.\nNevertheless, arguably this is not a bubble as the transition to EVs and subsequently AVs marks a major inflection. This means it is a large, largely greenfield growth opportunity. Hence, investors are willing to pay for this growth by investing in the companies who are leading. Moreover, EVs and AVs are also much closer aligned to tech investing, where higher valuations are more common.\nThis is, of course, in spite of automotive being notorious for its capital intensity. NIO for its part (partly) solves this by not producing its vehicles itself, but partnering for manufacturing.\nThere are other examples in tech where those who are seen as growth companies are rewarded with incredible valuations. For example, Nvidia has achieved almost 2x the valuation of Intel (INTC), despite over 3x lower revenue. TSMC (TSM) has over 2x the valuation of Intel despite almost 2x lower revenue. Of course, Nvidia and TSMC are growing faster than Intel, but that proves the point that high growth is often rewarded with perhaps unrealistic valuations.\nWith regards to NIO's valuation, it (still) has ~10x lower market cap than Tesla (to be precise, about 8x at the time of writing), but also ~10x lower deliveries. Hence, NIO's valuation is in line with its bigger peer.\nNevertheless, as a smaller company, it is arguably NIO who that the largest relative growth prospects ahead. For example, Tesla investors who want to see substantial shareholder returns going forward have to bank on Tesla's goal to achieve 20M deliveries by 2030, which would be over a fifth of the total global vehicle market.\nIf NIO for its part would be able to translate its innovation into continued, sustained growth, similar to Tesla, then there should be no reason for NIO to not continue to track the valuation of Tesla. This means NIO, indeed, may have another 10x upside or so if it closes the gap to Tesla in scale.\nFrom that view, NIO is lagging behind Tesla by multiple years, in both deliveries and market cap. The last comment could be as analogous to for examplePinterest(PINS), which is a company Iarguedwas lagging by several years to Facebook (FB).\nRisks\nOf course, there are major risks. Mainly, this thesis is based on two assumptions:\n\nTesla and other EV/AV stocks will continue to grow and receive elevated valuations as these trends continue to unfold;\nNIO is best positioned to most closely track Tesla's business and stock performance.\n\nAny decrease in (relative) valuation could result in downside. For example, Tesla's ambition as laid out at its fall 2020 Battery Day event called for Tesla to achieve a scale of 20 million units by 2030. Hence, it is likely at least some part of that ambition for further growth is already priced into the stock.\nNeedless to say, not every automotive or EV company will be able to achieve a scale of 20M units, as the global automotive market is below 100M units. There is both competition from traditional OEMs such as GM (GM) and Volkswagen, as well as other Chinese companiessuch as XPeng(XPEV).\nAdditionally, although China seems to be one the largest markets for EVs in the near future, Tesla itself has already built its own Gigafactory in China, further increasing competition. Although the reverse is also partly true given NIO's own international expansion.\nThe last risk for NIO growth it that is has expressed that it wants to remain a premium brand with relatively high ASPs (average selling prices). While this implies NIO could have above-average gross margins, it may nevertheless lower NIO's addressable market and hence potential future growth.\nFurther, while NIO is heavily investing in autonomous driving and seems to be at the forefront of this next major inflection, it is ultimately reliant on third-party silicon vendors like Nvidia. This insight means pretty much by definition that AV technology may not remain a differentiated capability, as others will be able to buy the same off-the-shelf systems. Although as noted NIO is developing its own software, that itselfis also a riskgiven the difficulty in creating a scalable and reliable AV system.\nAs described, though, NIO is a clear, leading innovator, and has achieved a strong brand value. This arguably makes it the strongest candidate to become the closest to a 'Chinese Tesla'.\nTakeaway\nIn the last 18 months or so, there has been a major shift in investment sentiment around EV companies. Tesla has seen 10-bagger returns. So when evaluating NIO, after its own 10-bagger returns (or more), to a valuation closer to $100B than $10B, on the surface this may change the investment narrative.\nHowever, at least a portion of NIO's large shareholder returns was because of its financial issues, which it has overcome; NIO's valuation is not significantly different from Tesla, for one. Meanwhile, its still much lower scale arguably leaves much room for upside.\nNIO's stock is based on NIO's growth to capitalize on the two-fold disruption of EVs and AVs in the automotive industry. NIO already has a proven track record of growth and innovation with battery swap, ADAS, autonomous driving (although with some increased risks given its change of supplier), ADaaS, BaaS, and even international expansion.\nWhile far from every company will be able to achieve a similar scale as Tesla, NIO clearly remains positioned to be successful in this space, which represents a large, greenfield opportunity in both the Chinese and international push towards electric and autonomous driving.\nThis means NIO's valuation is both the risk and the reward. The reward is that NIO could realistically still expand by another 10x if it continues to trade at a similar valuation as Tesla, while closing the gap in scale. I likened NIO to the Alibaba of EVs: the Chinese counterpart of Amazon in EVs. The risk is NIO's ability to execute and deliver on its growth opportunity, as well as (just as importantly) as Tesla's and other EV stocks' valuation not collapsing on changes in investor sentiment.\nThe bottom line (since NIO's peak in February) is that the potential opportunity that still lies ahead slightly outweighs the risk.","news_type":1},"isVote":1,"tweetType":1,"viewCount":57,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":121072307,"gmtCreate":1624446832009,"gmtModify":1703836934085,"author":{"id":"3573515033218465","authorId":"3573515033218465","name":"Kaboom","avatar":"https://static.tigerbbs.com/5cc3a179bc8939d7ec568911cc826578","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573515033218465","idStr":"3573515033218465"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CLOV\">$Clover Health Corp(CLOV)$</a>Whoah whoah slow down. It normally turns out bad once the market opens if it rises so quickly&nbsp;","listText":"<a href=\"https://laohu8.com/S/CLOV\">$Clover Health Corp(CLOV)$</a>Whoah whoah slow down. It normally turns out bad once the market opens if it rises so quickly&nbsp;","text":"$Clover Health Corp(CLOV)$Whoah whoah slow down. It normally turns out bad once the market opens if it rises so quickly","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":5,"repostSize":0,"link":"https://ttm.financial/post/121072307","isVote":1,"tweetType":1,"viewCount":1120,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3572494121485245","authorId":"3572494121485245","name":"gt96","avatar":"https://static.tigerbbs.com/f5c621467d68fd369e2a989ac58beb01","crmLevel":2,"crmLevelSwitch":1,"authorIdStr":"3572494121485245","idStr":"3572494121485245"},"content":"The other time premarket rise... when market open it hits 100%","text":"The other time premarket rise... when market open it hits 100%","html":"The other time premarket rise... when market open it hits 100%"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":117445233,"gmtCreate":1623159328322,"gmtModify":1704197306703,"author":{"id":"3573515033218465","authorId":"3573515033218465","name":"Kaboom","avatar":"https://static.tigerbbs.com/5cc3a179bc8939d7ec568911cc826578","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573515033218465","idStr":"3573515033218465"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CLOV\">$Clover Health Corp(CLOV)$</a>Buy at $17 &nbsp;","listText":"<a href=\"https://laohu8.com/S/CLOV\">$Clover Health Corp(CLOV)$</a>Buy at $17 &nbsp;","text":"$Clover Health Corp(CLOV)$Buy at $17","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/117445233","isVote":1,"tweetType":1,"viewCount":60,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}